Butinib 140 mg (Ibrutinib), general Imruvica is a traditional drug used to treat certain cancers similar to Mantle cell carcinoma (MCL), Habitual lymphocytic leukemia (CLL)/ small lymphocytic carcinoma, borderline zone carcinoma (MZL), Waldenstrom macroglobulinemia, Habitual graft-versus-host (cGVHD) complaint. Butinib is manufactured by Drug InternationalLtd. in Bangladesh.
Have to take orally formerly diurnal with a glass of water.
The most common adverse responses are
Thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, supplemental edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, skin rash, abdominal pain, puking, and loss of appetite.
The below information comes from the Internet. Please consult with a croaker for medical advice.
* Any advice on the use of the medicine is for reference only. Please consult with the croaker for medical advice. All Names, ensigns, and trademarks are the property of their separate possessors. Watermarks and QR canons are used for identification purposes only.